Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy - Todenhöfer, Tilman; Hennenlotter, Jörg; Leidenberger, Philipp; Wald, Alexander; Hohneder, Andrea; Kühs, Ursula; Mischinger, Johannes; Aufderklamm, Stefan; Gakis, Georgios; Blumenstock, Gunnar; Stenzl, Arnulf; Schwentner, Christian (BJU international, 2014)
Keywords: Adult; Aged; Biological and medical sciences; Biomarkers, Tumor - blood; Bone cancer; bone metastasis; Bone Neoplasms - blood; Bone Neoplasms - secondary; denosumab; Follow-Up Studies; Gynecology. Andrology. Obstetrics; Humans; Lymph Node Excision; Male; Male genital diseases; Medical sciences; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local - blood; Nephrology. Urinary tract diseases; osteoprotegerin (OPG); Osteoprotegerin - blood; Prognosis; prostate cancer; Prostatectomy - methods; Prostatic Neoplasms - blood; Prostatic Neoplasms - pathology; radical prostatectomy; RANK Ligand - blood; receptor activator of nuclear factor kB ligand (RANKL); recurrence; Retrospective Studies; Signal Transduction; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Nephrology; Prostate disease; Diseases of the osteoarticular system; osteoprotegerin (OPG); Receptor activator of nuclear factor kappa B; Monoclonal antibody; Biochemical recurrence; Urology; Osteoprotegerin; radical prostatectomy; Surgery; Transcription factor NFκB; receptor activator of nuclear factor kB ligand (RANKL); Male genital diseases; Serum factor; Biological receptor; Human; Urinary system disease; Receptor activator Nfkb ligand; Malignant tumor; Denosumab; Immunomodulator; recurrence; Bone metastasis; Treatment; Prostatectomy; Predictive factor; Prostate cancer; Cancer; prostate cancer; bone metastasis; denosumab